PRS22 THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2512
https://www.valueinhealthjournal.com/article/S1098-3015(19)34890-9/fulltext
Title :
PRS22 THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34890-9&doi=10.1016/j.jval.2019.09.2512
First page :
Section Title :
Open access? :
No
Section Order :
12198